INJURIA RENAL AGUDA EN LOXOSCELISMO, ASPECTOS INMUNO-HISTOPATOLÓGICOS

Una de las complicaciones más importantes y asociada a la mortalidad en el loxoscelismo sistémico (LS) es la injuria renal aguda (IRA)1. El mecanismo fisiopatológico no es conocido del todo, sin embargo, hay diversos estudios enfocados a encontrar la causa principal de la enfermedad. Un importante estudio, fue el realizado por Lucato et al2, que buscando demostrar a nivel experimental el daño citotóxico directo del veneno en las células de los túbulos renales al aplicarlo directamente sobre ellas (In Vitro), no encontraron lesiones, pero sí cuando se aplicó el veneno In Vivo, demostrando la importancia de los componentes sanguíneos en el origen del daño tisular, postulando la teoría que estos son componentes tanto del sistema inmune innato como adaptativo. En estudios que fueron realizados en tejidos de otros sistemas, muestran resultados similares. Experimentalmente se ha demostrado que la hemolisis es producto de la activación del complemento, que inicia posteriormente al daño producido en la membrana del eritrocito por acción del veneno y activación de las metaloproteinasas intraeritrocitarias. A nivel hepático y de otros tejidos, se ha encontrado infiltrado tisular por células inflamatorias con daño por apoptosis y lisis celular3,4. Adicionalmente, en un reporte clínico, se observó la positividad de la prueba de Coombs directa en hemolisis asociada a LS, dándonos una pista de la importancia del sistema inmunológico en la fisiopatología de la enfermedad5-7.   DOI: 10.25176/RFMH.v18.n2.129

Elaboración y validación de una regla de predicción clinica para identificar compromiso sistemico en casos de loxoscelismo: Preparation and validation of a systemic loxoscelism prediction protocol

Introduction: Systemic loxoscelism is the most severe complication of loxoscelism. The management of the cadre by health personnel presents a high variability due to factors that are currently unknown. There is no standard of reference or a clinical prediction model that can guide our decisions when approaching a spider bite patient. Objective: Develop and validate a clinical prediction rule for systemic loxoscelism. Methods: An observational study of derivation and validation of a clinical prediction model was carried out with diagnostic test validation based on a historical single-arm cohort in patients treated at Vitarte Hospital between 2007 and 2016 and international clinical reports published. Results: Systemic loxoscelism occurred only in 32.9% (n = 24) of cases. For the bivariate analysis, the variables that showed a statistically significant association (P <0.05) were sex, bite in an independent abdomen in relation to other parts of the body, bite in other parts of the body than the abdomen, vomiting , fever and hemoglobinuria. The regression analysis included in the analysis the variables: sex, vomit, fever and hemoglobinuria. Bootstrapping determined the internal validity of the model. The area under the curve was 0.91 (P <0.05) and the sensitivity, specificity, LR + and LR- were 79.1%, 93.8%, 12.9 and 0.22 respectively. Conclusions: The protocol of prediction of systemic derived loxoscelism is valid, for the moment.Introducción: El loxoscelismo sistémico es la complicación más severa del loxoscelismo. El manejo del cuadro por parte del personal de salud presenta una alta variabilidad por factores que se desconocen actualmente. No se cuenta con un estándar de referencia ni con un modelo de predicción clínica que pueda guiar nuestras decisiones al momento del abordaje de un paciente con mordedura de araña. Objetivo: Elaborar y validar una regla de predicción clínica para loxoscelismo sistémico. Métodos: Se llevó a cabo un estudio observacional de derivación y validación de un modelo de predicción clínica con validación de prueba diagnóstica basada en una cohorte histórica de un solo brazo en pacientes atendidos en el Hospital Vitarte entre los años 2007 al 2016 y reportes clínicos internacionales publicados. Resultados: El loxoscelismo sistémico se presentó solo en el 32,9 % (n=24) de casos. Para el análisis bivariado, las variables que demostraron presentar una asociación estadísticamente significativa (P<0,05) fueron el sexo, mordedura en abdomen independiente en relación a otras partes del cuerpo, mordedura en otras partes del cuerpo que no sea el abdomen, vómito, fiebre y hemoglobinuria. El análisis de regresión incluyó en el análisis a las variables: sexo, vómito, fiebre y hemoglobinuria. El bootstrapping determinó la validez interna del modelo. El área bajo la curva fue de 0,91 (P<0,05) y la sensibilidad, espeficidad, LR+ y LR- fueron de 79,1%, 93,8%, 12,9 y 0,22 respectivamente. Conclusiones: El protocolo de predicción del loxoscelismo sistémico derivado es válido, por el momento

Eficacia y seguridad en condiciones clínicas reales del raltegravir en un hospital de referencia del seguro social peruano

Introduction: Rategravir belongs to integrase inhibitors, being demonstrated and approved by several clinical trials as a powerful and safe antiretroviral drug for the treatment of patients infected with human immunodeficiency virus (HIV), with good tolerance and low toxicity, including in the third line or rescue scheme and it starts when the first and second lineas schemes have failed.Objective: To evaluate the efficacy and safety in real clinical conditions of the use of Raltegravir within the HAART schemes in patients with HIV infection in a reference hospital of social insurance in Peru.Methods: A retrospective observational study was performed in patients with a diagnosis of HIV infection who started treatment within the TARGA scheme based on Raltegravir with follow-up and control at 6 months. We presented summary measures of frequencies and percentages for the qualitative variables, as well as means and standard deviation for the quantitative variables based on the results of the normality tests. The data was processed and analyzed in the statistical software SPSS version 22.Results: The male gender was the most affected with 76% (n = 119) of the total. The most frequent age range was between 45 to 55 years (25.4%, n = 40). The most frequent comorbidities were Diabetes mellitus and arterial hypertension, with exponential reduction in viral load and elevation of CD4 lymphocyte levels.Conclusion: Raltegravir is effective for the treatment of HIV patients.Introducción: El Rategravir pertenece a los inhibidores de integrasas, quedando demostrado y aprobado por diversos ensayos clínicos como un potente antirretroviral seguro y eficaz para el tratamiento de pacientes infectados con el virus de inmunodeficiencia humana (VIH), con buena tolerancia y baja toxicidad, incluyéndose en el esquema de tercera línea o rescate y se inicia cuando los esquemas de primera y segunda línea han fracasado.Objetivo: Evaluar la eficacia y seguridad en condiciones clínicas reales del uso de Raltegravir dentro de los esquemas de la Terapia Antiretroviral de Gran Actividad (TARGA) en pacientes con infección por VIH en un hospital de referencia del seguro social en Perú.Métodos: Se realizó un estudio observacional retrospectivo en pacientes con diagnóstico de infección por VIH que iniciaron tratamiento dentro del esquema TARGA basados en Raltegravir con seguimiento y control a los 6 meses. Se presentaron medidas de resumen de frecuencias y porcentajes para las variables cualitativas, así como medias y desviación estándar para las variables cuantitativas en base a los resultados de las pruebas de normalidad. Los datos fueron procesados y analizados en el software estadístico SPSS versión 22.Resultados: El género masculino fue el más afectado con un 76%(n=119) del total. El rango de edad más frecuente fue el comprendido entre los 45 a 55 años (25,4%; n=40). Las comorbilidades más frecuentes fueron Diabetes mellitus e Hipertensión arterial, con reducción exponencial de la carga viral y elevación de los niveles de linfocitos CD4.Conclusión: El Raltegravir es eficaz para el tratamiento de pacientes VIH

Coinfecção entre Dengue e COVID-19: necessidade de abordagem em zonas endêmicas

El impacto que ha originado la enfermedad por coronavirus 2019 (COVID-19) en diferentes partes del mundo, alcanza en la actualidad 597. 072 personas contagiadas y 27.364 fallecidas según los últimos reportes. En ese contexto, en el Perú, una zona de relevancia epidemiológica es la amazonia, debido a la distribución de enfermedades endémicas como las enfermedades metaxénicas (Dengue, Malaria entre otras), en donde el problema se incrementa debido a que la infección por COVID-19 puede llevar a falsos positivos en las pruebas de cribado para Dengue. Conllevando de esa forma a un retraso en el diagnóstico de la infección por COVID-19 y una mayor diseminación del virus, debido a que en la mayor parte de los casos de Dengue no se presentan signos de alarma y el tratamiento es ambulatorio. Este artículo busca emitir una opinión sobre la necesidad del abordaje de casos de coinfección entre Dengue y Covid-19 en zonas endémicas.The impact caused by the 2019 coronavirus disease (COVID-19) in different parts of the world, currently reaches 745, 308 infected and 35,307 deaths according to the latest reports. In this context, in our country, an area of epidemiological relevance is the Peruvian Amazon, due to the distribution of endemic diseases such as metaxemic diseases (Dengue, Malaria, among others), where the problem increases due to the COVID infection. -19 can lead to false positives in Dengue screening tests. Thus leading to a delay in the diagnosis of COVID-19 infection and further spread of the virus, since in most cases of Dengue there are no warning signs and treatment is ambulatory. This article seeks to express an opinion on the need to address cases of coinfection between Dengue and Covid-19 in endemic areas.O impacto causado pela doença de coronavírus 2019 (COVID-19) em diferentes partes do mundo atinge atualmente 745, 308 infectados e 35.307 mortes, de acordo com os últimos relatórios. Nesse contexto, em nosso país, uma área de relevância epidemiológica é a Amazônia peruana, devido à distribuição de doenças endêmicas, como as metaxêmicas (Dengue, Malária, entre outras), onde o problema aumenta devido à infecção por COVID. -19 pode levar a falsos positivos nos testes de rastreamento da dengue. Isso leva a um atraso no diagnóstico da infecção por COVID-19 e a uma maior disseminação do vírus, porque na maioria dos casos de dengue não há sinais de alerta e o tratamento é ambulatorial.Este artigo procura expressar uma opinião sobre a necessidade de abordar casos de co-infecção entre Dengue e Covid-19 em áreas endêmicaspublishedVersionFil: Saavedra Velasco, Marcos. Universidad Ricardo Palma; Perú.Fil: Chiara Chilet, Christian. Instituto Nacional de Salud del Niño San Borja; Perú.Fil: Pichardo Rodriguez, Rafael. Universidad Ricardo Palma. Instituto de Investigación en Ciencias Biomédicas; Perú.Fil: Grandez Urbina, Antonio. Universidad Continental; Perú.Inga Berrospi, Fiorella. Universidad Privada Norbert Wiener. Centro de Investigación; Perú

Alteraciones morfológicas de las médulas óseas en pacientes con covid-19. revision sistemática y meta-análisis

Introduction: Despite the fact that hematological alterations at the peripheral level are widely known, little is known about the alterations caused by COVID-19 at the bone marrow level. Objective: To determine the morphological alterations of the bone marrow caused by COVID-19. Material and methods: Systematic review and meta-analysis. Observational studies and reports and case series were included and editorials, reviews, letters to the editor were excluded. A search was performed in Pubmed, ScienceDirect and Scielo. The risk of bias was assessed using the NewCatell-Ottawa and Hassan Murad scales for case reports and series. The outcomes were the morphological parameters of the bone marrow. For the quantitative synthesis of the information, a proportion meta-analysis was performed using random effects in RStudio. Results: Hypercellularity occurred in 65% (95% CI: 51%-78%), maturation arrest of the myeloid series occurred in 57% (95% CI: 29%-83%). and the alteration of the M/E ratio occurred in 60% (95% CI: 46%-74%). Conclusion: The most frequent morphological alterations in the bone marrow were hypercellularity, arrest in myeloid maturation and alteration of the M/E ratio in patients with COVID-19.Introducción: Pese a conocerse ampliamente las alteraciones hematológicas a nivel periférico, aún es poco lo que se conoce acerca de las alteraciones originadas por la COVID-19 a nivel de la médula ósea. Objetivo: Determinar las alteraciones morfológicas de la médula ósea causadas por la COVID-19. Material y Métodos: Revisión sistemática y meta-análisis. Se incluyeron estudios observacionales y reportes y series de caso y se excluyeron a editoriales, revisiones y cartas al editor. Se realizó una búsqueda estructurada en Pubmed, ScienceDirect y Scielo. El riesgo de sesgo se evaluó mediante la escala NewCatell-Otawa y de Hassan Murad para los reportes y series de caso. Los desenlaces fueron los parámetros morfológicos de la médula ósea. Para la síntesis cuantitativa de la información se realizó un meta-análisis de proporción mediante efectos aleatorios en RStudio. Resultados: La hipercelularidad se presentó en el 65% (IC-95%: 51%-78%), la detención de la maduración de la serie mieloide se presentó en el 57% (IC-95%: 29%-83%) y la alteración de la relación M/E se presentó en el 60% (IC-95%: 46%-74%). Conclusión: Las alteraciones morfológicas en la médula ósea más frecuentes fueron la hipercelularidad, detención en la maduración mieloide y alteración de la relación M/E en los pacientes con COVID-19

Situación del mapeo microbiológico de uro cultivos en un hospital referencial de Perú 2013-2015: Situation of the microbiological mapping of urine cultures in a referral hospital of Peru 2013-2015

Abstract   Microbiological mapping is a tool and base for good antibiotic management. It guides the empirical treatments in the hospital services as well as in the updating of care protocols. Objective: To determine the situation of the microbiological mapping of urine cultures in referential hospital. Methods: A cross-sectional descriptive study of urine cultures of the different hospital services from the first semester of 2013 to 2015 was carried out. The situation was defined as the determination of the microbiological profile and the most frequent pathogens isolated. The percentage of resistance by extended-spectrum beta-lactamase (ESBL) for 3 consecutive years was determined. The data were collected and added to a database coded in double back up. Results: The most frequently isolated pathogens were E. coli (56.60%), K. pneumoniae (10.12%) and P. mirabilis (4.22%). The frequency of E. coli ESBL (+) in the years 2013, 2014, 2015 was 37.49%; 47.02% and 50.10% respectively. The sensitivity of E. coli was for ertapenem, meropenem and imipenem (99% -100%), tigecillin (99%) and the percentage of resistance of E. coli to Ciprofloxacin: 67%, 72% and 82% respectively. Conclusion: The most frequently isolated agent was E. coli. The frequency of E. coli ESBL (+) has increased by 33% (2013) to 50% by 2015, with an increase in resistance to ciprofloxacin. However, there is a therapeutic alternative (cefotaxime / clavulanic acid) whose sensitivity is greater than 90%. Key words: Microbiological analysis; Escherichia coli; Antibiotic therapy. (source: MeSH NLM) DOI: https://doi.org/10.25176/RFMH.v18.n1.126

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk assessment

Background: High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010. Methods: We used data for exposure to risk factors by country, age group, and sex from pooled analyses of population-based health surveys. We obtained relative risks for the effects of risk factors on cause-specific mortality from meta-analyses of large prospective studies. We calculated the population attributable fractions for each risk factor alone, and for the combination of all risk factors, accounting for multicausality and for mediation of the effects of BMI by the other three risks. We calculated attributable deaths by multiplying the cause-specific population attributable fractions by the number of disease-specific deaths. We obtained cause-specific mortality from the Global Burden of Diseases, Injuries, and Risk Factors 2010 Study. We propagated the uncertainties of all the inputs to the final estimates. Findings: In 2010, high blood pressure was the leading risk factor for deaths due to cardiovascular diseases, chronic kidney disease, and diabetes in every region, causing more than 40% of worldwide deaths from these diseases; high BMI and glucose were each responsible for about 15% of deaths, and high cholesterol for more than 10%. After accounting for multicausality, 63% (10·8 million deaths, 95% CI 10·1-11·5) of deaths from these diseases in 2010 were attributable to the combined effect of these four metabolic risk factors, compared with 67% (7·1 million deaths, 6·6-7·6) in 1980. The mortality burden of high BMI and glucose nearly doubled from 1980 to 2010. At the country level, age-standardised death rates from these diseases attributable to the combined effects of these four risk factors surpassed 925 deaths per 100 000 for men in Belarus, Kazakhstan, and Mongolia, but were less than 130 deaths per 100 000 for women and less than 200 for men in some high-income countries including Australia, Canada, France, Japan, the Netherlands, Singapore, South Korea, and Spain. Interpretation: The salient features of the cardiometabolic disease and risk factor epidemic at the beginning of the 21st century are high blood pressure and an increasing effect of obesity and diabetes. The mortality burden of cardiometabolic risk factors has shifted from high-income to low-income and middle-income countries. Lowering cardiometabolic risks through dietary, behavioural, and pharmacological interventions should be a part of the global response to non-communicable diseases. Funding: UK Medical Research Council, US National Institutes of Health. © 2014 Elsevier Ltd

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Summary Background Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents. Methods For this pooled analysis, we used a database of cardiometabolic risk factors collated by the Non-Communicable Disease Risk Factor Collaboration. We applied a Bayesian hierarchical model to estimate trends from 1985 to 2019 in mean height and mean BMI in 1-year age groups for ages 5–19 years. The model allowed for non-linear changes over time in mean height and mean BMI and for non-linear changes with age of children and adolescents, including periods of rapid growth during adolescence. Findings We pooled data from 2181 population-based studies, with measurements of height and weight in 65 million participants in 200 countries and territories. In 2019, we estimated a difference of 20 cm or higher in mean height of 19-year-old adolescents between countries with the tallest populations (the Netherlands, Montenegro, Estonia, and Bosnia and Herzegovina for boys; and the Netherlands, Montenegro, Denmark, and Iceland for girls) and those with the shortest populations (Timor-Leste, Laos, Solomon Islands, and Papua New Guinea for boys; and Guatemala, Bangladesh, Nepal, and Timor-Leste for girls). In the same year, the difference between the highest mean BMI (in Pacific island countries, Kuwait, Bahrain, The Bahamas, Chile, the USA, and New Zealand for both boys and girls and in South Africa for girls) and lowest mean BMI (in India, Bangladesh, Timor-Leste, Ethiopia, and Chad for boys and girls; and in Japan and Romania for girls) was approximately 9–10 kg/m2. In some countries, children aged 5 years started with healthier height or BMI than the global median and, in some cases, as healthy as the best performing countries, but they became progressively less healthy compared with their comparators as they grew older by not growing as tall (eg, boys in Austria and Barbados, and girls in Belgium and Puerto Rico) or gaining too much weight for their height (eg, girls and boys in Kuwait, Bahrain, Fiji, Jamaica, and Mexico; and girls in South Africa and New Zealand). In other countries, growing children overtook the height of their comparators (eg, Latvia, Czech Republic, Morocco, and Iran) or curbed their weight gain (eg, Italy, France, and Croatia) in late childhood and adolescence. When changes in both height and BMI were considered, girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries (eg, Armenia and Azerbaijan), and boys in central and western Europe (eg, Portugal, Denmark, Poland, and Montenegro) had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI. The unhealthiest changes—gaining too little height, too much weight for their height compared with children in other countries, or both—occurred in many countries in sub-Saharan Africa, New Zealand, and the USA for boys and girls; in Malaysia and some Pacific island nations for boys; and in Mexico for girls. Interpretation The height and BMI trajectories over age and time of school-aged children and adolescents are highly variable across countries, which indicates heterogeneous nutritional quality and lifelong health advantages and risks